ALK-Abello A/S Eulerpool Uudised

ALK-Abello A/S aktsia uudised

ALK-Abello A/S jälgivad paljud ajakirjanikud ja investorid üle kogu maailma. Kõige värskemad ALK-Abello A/S uudised paneme siia kokku.

• 14. august ·

  Yahoo
  Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025
• 12. august ·

  Yahoo
  ALK upgrades its full-year revenue outlook
• 12. august ·

  Yahoo
  Peanut Allergy Treatment Market Report 2025-2033, with Key Player Profiles for Aimmune Therapeutics, DBV Technologies, Sanofi, ALK-Abello, Prota Therapeutics, Camallergy, Aravax, and Genentech
• 21. juuli ·

  Yahoo
  ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system
• 18. juuli ·

  Yahoo
  MHRA approves needle-free adrenaline nasal spray for anaphylaxis
• 18. juuli ·

  Yahoo
  EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
• 18. juuli ·

  Yahoo
  EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
• 9. juuli ·

  SeekingAlpha
  ARS Pharmaceuticals: 'Betting On The Come'
• 26. juuni ·

  Yahoo
  First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
• 16. juuni ·

  Yahoo
  ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025